TQB3454

TQB3454 is a small-molecule drug developed by Chia Tai Tianqing Pharmaceutical. Its target is IDH1 / IDH2 (the sponsor names IDH1 (mutant)). The sponsor states: Selective inhibitor of mutant IDH1 enzyme, given as an oral tablet, being tested against placebo in advanced biliary tract cancer patients with IDH1 mutations. ClinicalTrials.gov describes the intervention as: TQB3454 is a selective IDH1 mutant enzyme inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05987358 (A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma), in biliary tract cancer. The largest, NCT05987358, plans to enrol 165 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.